HCV NS3 protease inhibitors

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

Y is CH or N;

R 1 is:

—OC 1-6 alkyl,

—OC 1-6 alkyl-het 1 ,

—OC 1-6 alkyl-OH,

—OC 1-6 alkyl-NR a R b ,

—O-het 1 ,

—OC 1-6 alkylCO 2 H,

—OC 1-6 alkylC(═O)-het 1 ,

—O(CH 2 ) 1-6 OC(═O)CH 2 NR a R b ,

—OC 1-6 alkyl-C 1-6 alkoxy,

—OC 1-6 alkyl-C 1-6 alkoxy-C 1-6 alkoxy,

—OC(O)NR a R b ,

—OC 1-6 alkyl-S-het 1 ,

—OC 1-6 alkyl-phosphate,

a phosphate group,

—(CH 2 ) 1-6 -het 1 ,

pyridinyl, or

thiazolyl;

wherein

said alkyl is optionally substituted with 1 or 2 fluoro substituents,

said phosphate group is optionally substituted with 1, 2 or 3 C 1-6 alkyl;

said het 1 is:

a) naphthyl optionally substituted with 1 or 2 substituents selected from —OH, C 1-6 alkyl, or halo;

b) heteroaryl selected from 5- and 6-membered aromatic rings having 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein said heteroaryl is attached through a ring atom selected from C or N and optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl and —OH; or

c) heterocycle selected from 4-7 membered monocyclic or 6-10 membered polycyclic bridged, linearly fused or spirocyclic saturated or unsaturated non-aromatic rings having 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, wherein said heterocycle is attached through a ring atom selected from C or N and optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, oxo, —(CH 2 ) m F, Boc, —(CH 2 ) m CF 3 , —(CH 2 ) m OCF 3 , —OH, —NR a R b , —C 1-6 alkoxy, —(CH 2 ) m SO 2 CH 3 , aryl, —C 1-6 alkoxy-C 1-6 alkyl, —C 1-6 alkyl-C 1-6 alkoxy optionally substituted with CF 3 , cyano, C(═O)NH 2 , C 3-6 cycloalkyl,

—C 1-6 alkyl-C 3-6 cycloalkyl, —COOC 1-6 alkyl,

C 1-6 alkyl-SO 2 C 1-6 alkyl, and benzimidazolyl wherein the benzimidazolyl is optionally substituted with F;

R a and R b are independently selected from H; C 1-6 alkyl; t-Boc; aryl; C 3-6 cycloalkyl optionally substituted with 1 or 2 fluoro; C 1-6 alkoxy-C 1-6 alkyl; tetrahydropyranyl; C 1-6 alkyl-OH; C 1-6 alkyl-arylA; C 1-6 alkyl-C(H)(OH)-arylA; C 1-6 alkyl-imidazolyl optionally substituted with methyl, C 1-6 alkyl-benzimidazolyl optionally substituted with methyl; C 1-6 alkyl-pyrazolyl; C 1-6 alkyl-dihydrotriazole optionally substituted with oxo; or C 1-6 alkyl-pyrrolidinyl optionally substituted with oxo;

wherein

m is 0 or 1 to 4;

said arylA is phenyl, naphthalenyl, tetrahydronaphthalenyl, or 7-10 membered fused bicyclic ring structure wherein at least one of the rings is aromatic and is optionally substituted with 2 —OH;

said tetrahydropyranyl is optionally substituted with 1 oxo;

R 2 is C 1-6 alkyl, C 2-6 alkenyl, C 3 -C 6 cycloalkyl or NR c R d ;

wherein

the C 3-6 cycloalkyl is optionally substituted with C 1-6 alkyl optionally substituted with —OH, morpholinyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkoxy,

C 1-6 alkoxy-phenyl, or C 2-6 alkenyl;

R c and R d are independently H or C 1-6 alkyl, or may be taken together, with the N to which they are attached, to form a 4-7-membered monocyclic ring;

R 3 is C 1-6 alkyl, C 2-6 alkenyl, C 3 -C 6 cycloalkyl, CHF 2 or CF 3 ;

R 4 is C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkyl-C 3-8 cycloalkyl, adamantyl, dihydroindenyl, or a 4-8 membered heterocycloalkyl having 1 or 2 heteroatoms selected from N, O, or S, wherein R 4 is optionally substituted with one or two substituents independently selected from (C 1 -C 6 )alkyl, halo, and —O(C 1 -C 6 )alkyl; or

R 3 and R 4 together form heptene;

Z is C or N;

R 5 is H or C 1-6 alkyl; or R 5 is absent when Z is N;

W is a bond, O or NR;

R is H or C 1-6 alkyl;

X is absent or is halo, CF 3 , —OCHF 2 , —OCH 2 F, —OCD 2 F, —OCDF 2 , C 1 -C 6 alkyl, C 1-6 alkoxy, aryl, heteroaryl, or —O(CH 2 ) 1-6 NR a R b ;

A is absent, O or N;

B is (CH 2 ) m ; and

n is 1-4.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, having a formula of

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, having a formula of

4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, having a formula of

5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H or CH 3 .

6. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is ethyl, ethylene, or cyclopropyl.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is propyl, t-butyl, cyclopentyl, cyclohexyl optionally substituted with 1 or 2 F, cyclohexylmethyl, methylcyclohexyl, methylcyclopentyl, dihydroindenyl, or tetrahydro-2H-pyranyl.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 1 to 3.

9. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is cyclopropyl, N(CH 3 ) 2 , or azetidinyl, wherein the cyclopropyl is optionally substituted with methyl, CH(CH 3 ) 2 , C(CH 3 )═CH 2 , C(CH 3 ) 2 OH, CH 2 CH 2 -morpholinyl, CH 2 OCH 3 , CH 2 OCH 2 CH 2 OCH 3 , or CH 2 OCH 2 -phenyl.

10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —O—C 1-6 alkyl;

—OC 1-6 alkyl-het 1 ; —OC 1-6 alkyl-C 1-6 alkoxy;

—OC 1-6 alkyl-C 1-6 alkoxy-C 1-6 alkoxy; —OCH 2 C(═O)-het 1 ; —O(CH 2 ) 1-6 OC(═O)CH 2 NR a R b ;

—OC(O)NR a R b ; —OC 1-6 alkyl-phosphate; —OC 1-6 alkyl-S-het 1 ; —O-het 1 ; —O—C 1-6 alkyl-OH optionally substituted with 1 or 2 fluoro substituents; or —OC 1-6 alkyl-NR a R b

wherein R a and R b are independently

H,

C 1-6 alkyl,

t-Boc,

C 3-6 cycloalkyl optionally substituted with 1 or 2 fluoro substituents,

C 1-6 alkyl-C 1-6 alkoxy,

C 1-6 alkyl-OH, phenyl,

C 1-6 alkyl-phenyl,

tetrahydropyranyl,

C 1-6 alkyl-C(H)(OH)-phenyl,

naphthalenyl,

C 1-6 alkyl-naphthalenyl,

C 1-6 alkyl-oxopyrrolidinyl,

C 1-6 alkyl-benzimidazolyl optionally substituted with methyl,

C 1-6 alkyl-pyrazolyl,

C 1-6 alkyl-dihydrotriazole optionally substituted with oxo, or

C 1-6 alkyl-imidazolyl optionally substituted with methyl.

11. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the het 1 is: oxazepanyl; oxooxazolidinyl; pyridinyl; pyrazolyl; pyrrolyl; tetrahydropyranyl; triazolyl optionally substituted with C 1-6 alkyl; dioxolanyl; oxoimidazolidinyl; morpholinyl optionally substituted with dimethyl or ethyl; pyrrolidinyl optionally substituted with 1 or 2 substituents independently selected from oxo, Boc, C 1-6 alkyl, OH, C(O)NH 2 , dimethylamino, and methylsulfonyl; piperidinyl optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl optionally substituted with CF 3 , cyclopropyl-C 1-6 alkyl, cyclopropyl, —(CH 2 ) m F, OH, —C 1-6 alkyl-SO 2 C 1-6 alkyl, —(CH 2 ) m CF 3 , —COOC 1-6 alkyl, Boc, and benzimidazolyl; imidizolyl; thiazolyl optionally substituted with methyl; azabicycloheptyl; azaspiroheptyl; azaspirononyl; oxaazabicycloheptyl; oxaazaspiroheptyl optionally substituted with methoxyethyl; azetidinyl optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, fluoro, OH, phenyl and Boc; dioxidothiomorpholinyl; piperazinyl optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, C 1-6 alkyl-cyclopropyl, CF 3 , methylsulfonyl, Boc, and oxo; azabicyclooctyl substituted with C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, —COOC 1-6 alkyl, or —(CH 2 ) m CF 3 ; oxaazabicyclononyl optionally substituted with Boc, C 1-6 alkyl, —COOC 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl or cyclopropylC 1-6 alkyl; or azabicyclooctanyl optionally substituted with C 1-6 alkyl.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is absent or selected from —Br, —Cl, —F, methoxy, methyl, propyl and CF 3 .

13. A compound according to claim 1 selected from:

or a pharmaceutically acceptable salt thereof.

14. A compound selected from:

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-3,15,33-trioxo-26-[2-(piperidin-1-yl)ethoxy]-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-26-[2-(morpholin-4-yl)ethoxy]-3,15,33-trioxo-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-26-[3-(morpholin-4-yl)propoxy]-3,15,33-trioxo-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-3,15,33-trioxo-26-[2-(pyrrolidin-1-yl)ethoxy]-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)-26-methoxy-N-[(1-methylcyclopropyl)sulfonyl]-3,15,33-trioxo-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-26-[2-(morpholin-4-yl)ethoxy]-3,15,33-trioxo-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,27,28,29,30,31,31a-docosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-3,15,33-trioxo-26-[3-(piperidin-1-yl)propoxy]-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide;

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-3,15,33-trioxo-26-[3-(pyrrolidin-1-yl)propoxy]-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18,19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide; or

(1aR,5S,11Z,12aS,13aR,16S,19R,27E,31aR)—N-[(1-methylcyclopropyl)sulfonyl]-26-[3-(4-methylpiperazin-1-yl)propoxy]-3,15,33-trioxo-1,1a,3,4,5,6,7,8,9,10,12a,13,15,16,18, 19,29,30,31,31a-icosahydro-5,17:16,19-dimethanodicyclopropa[12,13:28,29][1,20,3,14,17]dioxatriazacyclononacosino[21,22-b]quinoline-13a(14H)-carboxamide,

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising an effective amount of the compound according to claim 1 , and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15 , further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.

17. The pharmaceutical composition according to claim 16 , wherein the second therapeutic agent is ribavirin.